Attached To Or Within Viable Or Inviable Whole Micro-organism, Cell, Virus, Fungus Or Specified Sub-cellular Structure Thereof (e.g., Platelet, Red Blood Cell) Patents (Class 424/1.17)
-
Publication number: 20100166651Abstract: The present invention provides a radiotherapeutic composition comprising a high specific activity tin-117m source of radiotherapeutic atomic electrons and a delivery vehicle, e.g., a chelator or nanosphere or microsphere effective to contain tin-117m therein. The present invention also provides a targeting moiety linked to the delivery vehicle. Further provided are methods of treating a bone-associated pathophysiological condition or imaging the same using the high specific activity radiotherapeutic compositions.Type: ApplicationFiled: December 19, 2006Publication date: July 1, 2010Inventor: Marlene OLIVER
-
Publication number: 20100135902Abstract: Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP)Type: ApplicationFiled: May 1, 2008Publication date: June 3, 2010Inventors: Jeff Roberts, Douglas R. Lowy, John T. Schiller
-
Patent number: 7648695Abstract: New chemotherapeutic medicaments and certain medical uses and methods for use of such chemotherapeutic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. Preferably, the halogenated xanthene is Rose Bengal or a functional derivative of Rose Bengal. The halogenated xanthenes constitute a family of useful chemotherapeutic agents that afford selective, persistent accumulation in certain tissues.Type: GrantFiled: July 6, 2001Date of Patent: January 19, 2010Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott
-
Publication number: 20090246125Abstract: An image enhancing agent of a form comprising an effective quantity of an image enhancing material chemically or physically bound to or encapsulated within a support comprising, preferentially, an exine coating of spores of various plants or fungi, optionally with further excipients.Type: ApplicationFiled: December 14, 2005Publication date: October 1, 2009Inventors: Stephen Lawrence Atkin, Stephen Thomas Beckett, Grahame Mackenzie
-
Patent number: 7547536Abstract: A method of detecting the presence and quantity of bacterial spores, which includes adding an electrophilic alcohol and an acid anhydride to a sample, admixing the sample with a solvent, and analyzing the sample. The sample may be analyzed by injecting the mixture into a gas chromatograph equipped with a mass spectra detector.Type: GrantFiled: May 31, 2002Date of Patent: June 16, 2009Assignee: JEOL USA, Inc.Inventors: James A. Laramée, Robert B. Cody
-
Publication number: 20090123366Abstract: In order to target a diseased material in a subject, a monocyte, or monocyte-derived cell, such as a macrophage, which incorporates a magnetic material, such as a magnetic particle or a ferrofluid, preferably having a biocompatible coating, is proposed to be administered. A magnetic energy source may then be applied to the subject to destroy, rupture or inactivate the diseased material. Alternatively, the monocyte or monocyte derived cell may additionally include a therapeutic agent, which is thereby targeted at the diseased material.Type: ApplicationFiled: April 3, 2007Publication date: May 14, 2009Applicant: Keele UniversityInventors: Jon Dobson, Claire Lewis, Helen Byrne
-
Publication number: 20090117034Abstract: Modified viruses encoding transporter proteins and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses also can be used in diagnostic methods, such detection and imaging of tumors. The viruses also can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents.Type: ApplicationFiled: June 13, 2008Publication date: May 7, 2009Inventors: Nanhai Chen, Aladar A. Szalay, Yong A. Yu, Qian Zhang, Yuman Fong
-
Publication number: 20090016956Abstract: Methods of making and using labeled macrophages are described.Type: ApplicationFiled: April 28, 2008Publication date: January 15, 2009Inventors: Robert Bender, Allan M. Green, Perry Kim, Robert Kisilevsky, Douglas S. McNair, Shui-pang Tam
-
Publication number: 20080193373Abstract: Described herein are methods for detecting a microorganism or cell in a subject and methods for detecting, imaging or diagnosing a site, disease, disorder or condition in a subject using microorganisms or cells. Also described are methods which use microorganisms or cells for treating a disease, disorder or condition. Such sites, diseases and disorders include sites of cell proliferation, proliferative conditions, neoplasms, tumors, neoplastic disease, wounds and inflammation. Further described are microorganisms and cells for use in the methods and compositions, combinations and kits, including diagnostic and pharmaceutical compositions, containing a microorganism or cell. Microorganisms and cells described herein include those that bind, sequester or accumulate metal, such as those that provide for metal acquisition, transport, storage and/or metabolism. Additional imaging and therapy agents are also described.Type: ApplicationFiled: July 11, 2007Publication date: August 14, 2008Inventors: Jochen Harald Stritzker, Phil Hill, Aladara A. Szalay, Yong A. Yu
-
Patent number: 7404945Abstract: A diagnostic reagent for use in the evaluation of a pharmacological effect of a medicine containing a pharmaceutical agent including an enzyme, an enzyme inhibitor or a receptor ligand or a prodrug of the pharmaceutical agent is provided. Further, a method of screening pharmaceutical agents each comprising an enzyme, an enzyme inhibitor or a receptor ligand and/or prodrugs of the pharmaceutical agents is provided.Type: GrantFiled: February 20, 2003Date of Patent: July 29, 2008Assignee: Tokyo Gas Company LimitedInventors: Asuka Ito, Tadashi Kohno, Isaburo Hosoi, Junko Hirayama, Kenji Maeda
-
Patent number: 7402299Abstract: New intracorporeal photodynamic medicaments and certain medical uses and methods for use of such photodynamic medicaments for treatment of disease in human or animal tissue are described, wherein a primary active component of such medicaments is a halogenated xanthene or halogenated xanthene derivative. In preferred embodiments, such medicaments are used for treatment of a variety of conditions affecting the skin and related organs, the mouth and digestive tract and related organs, the urinary and reproductive tracts and related organs, the respiratory tract and related organs, the circulatory system and related organs, the head and neck, the endocrine and lymphoreticular systems and related organs, various other tissues, such as connective tissues and various tissue surfaces exposed during surgery, as well as various tissues exhibiting microbial or parasitic infection.Type: GrantFiled: November 30, 2004Date of Patent: July 22, 2008Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy C. Scott, Eric A. Wachter, Walter G. Fisher, John Smolik
-
Patent number: 7384623Abstract: High energy phototherapeutic agents or radiosensitizer agents comprised of a halogenated xanthene, or other related agents that exhibit a preference for concentration in biologically sensitive structures in diseased tissue, and methods of treating and imaging using such radiosensitizer agents in such diseased tissue are described herein.Type: GrantFiled: August 25, 1999Date of Patent: June 10, 2008Assignee: Provectus Pharmatech, Inc.Inventors: H. Craig Dees, Timothy Scott, John T. Smolik, Eric A. Wachter
-
Patent number: 7374875Abstract: The present invention relates to a family of peptides exhibiting high affinity and specificity for the viral protein gp120, to methods for producing these peptides, and to the use of these peptides.Type: GrantFiled: January 21, 2002Date of Patent: May 20, 2008Assignee: Commissariat a l'Energie AtomiqueInventors: Claudio Vita, Loic Martin, Christian Roumestand, Francisco Veas
-
Patent number: 7247501Abstract: According to the present invention, there is provided a delivery vehicle including sickle red blood cells carrying a moiety. The moiety can be any type of diagnostic or therapeutic agent. The present invention further provides for a method of diagnosing systemic hypoxia, acidosis, or hypertonicity by administering sickle red blood cells to a patient and detecting the location of the sickle red blood cells. Additionally, the present invention provides for a method of therapeutic treatment of systemic hypoxia, acidosis, or hypertonicity by administering sickle red blood cells to a patient. Further, the present invention provides for a delivery vehicle that specifically localizes or concentrates at systemic hypoxia, acidosis, or hypertonicity areas. The delivery vehicle is used in diagnosing and therapeutically treating these areas of hypoxia, acidosis, or hypertonicity also. The present invention further provides for a method of making the delivery vehicle described herein.Type: GrantFiled: June 22, 2001Date of Patent: July 24, 2007Assignees: Henry Ford Health System, Wayne State UniversityInventors: Jae Ho Kim, Stephen Lawrence Brown, Paul S. Swerdlow
-
Patent number: 7186398Abstract: A novel nanoscale, metal particle containing Fe atoms and Au atoms in solid solution. The particle is superparamagnetic with a large magnetic susceptibility at room temperature, is resistant to oxidation, and can be readily functionalized for use in diverse applications by attaching organic molecules to its surface.Type: GrantFiled: February 24, 2003Date of Patent: March 6, 2007Assignee: Purdue Research FoundationInventors: Ronald P. Andres, Alicia T. Ng
-
Patent number: 6913767Abstract: Methods and compositions are provided for the encapsulation of antigens in PLGA microspheres for use as vaccines. Such microspheres can also contain adjuvants. Mixtures of microspheres are provided which release antigen at desired intervals to provide boosts with antigen.Type: GrantFiled: April 30, 1997Date of Patent: July 5, 2005Assignee: Genentech, Inc.Inventors: Jeffrey L. Cleland, Amy Lim, Michael Frank Powell
-
Patent number: 6818199Abstract: Metal nanoparticles are described that are useful for enhancing the contrast of x-rays or other radiation sources. A method is disclosed whereby the agents are administered intravenously or intra-arterially to detect coronary senses and other vascular features. It is also disclosed how directing moieties attached to the metal particles are used to detect specific targets.Type: GrantFiled: March 8, 2002Date of Patent: November 16, 2004Inventors: James F. Hainfeld, Daniel N. Slatkin
-
Patent number: 6783751Abstract: The invention relates to a novel method for the in-vivo labeling of biopolymers such as proteins, nucleic acids, lipids, carbohydrates and biodegradable plastic using isotopes, especially stabile isotopes. The invention also relates to the use of chemolithotrophic bacteria for the in-vivo isotopic labeling of biopolymers. In particular, the invention relates to the use of CO2-fixing bacteria, such as Ralstonia eurtropha and related methanogenic bacteria for the in-vivo isotopic labeling, especially for labeling using the stable isotope 13C alone and in combination with other isotopes. In addition, the invention relates to the use of isotropically labeled biomolecules in therapeutic and diagnostic applications, especially in spectroscopic methods and generally as tracers.Type: GrantFiled: February 27, 2001Date of Patent: August 31, 2004Assignee: Silantes GmbHInventor: Hermann Heumann
-
Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
Patent number: 6645464Abstract: Delivery of metal particles to living tissue, then applying external energy that interacts with the metal particles, is found to selectively increase the energy deposition and interaction surrounding the metal particles. The method is useful to improve treatment of various conditions, since targeted cells may be selectively altered or killed. Metal particles are also loaded into cells or membrane vesicles by placing metal seed particles into the cells or vesicles, then chemically depositing additional metal on the metal seed particles. The metal particles are useful to improve imaging and therapies by their interaction with externally applied energy.Type: GrantFiled: July 29, 1999Date of Patent: November 11, 2003Inventor: James F. Hainfeld -
Patent number: 6379647Abstract: The invention relates to the imaging, preferably of hypoxic or ischaemic sites using mononuclear phagocytes. Specifically, the migratory behavior of the mononuclear phagocytes is exploited with a view to targeting imaging agents to sites that mononuclear phagocytes penetrate.Type: GrantFiled: November 8, 1999Date of Patent: April 30, 2002Assignee: Oxford Biomedica (UK) LimitedInventor: Claire Elizabeth Lewis
-
Patent number: 6361758Abstract: Stable pharmaceutical formulations of a therapeutic agent, a low molecular weight alcohol and a glycol derivative are disclosed. Preferred formulations include 19-nor-1&agr;,3&bgr;,25-trihydroxy-9,10-secoergosta-5,7(E),22(E)-triene.Type: GrantFiled: October 12, 2000Date of Patent: March 26, 2002Assignee: Abbott LaboratoriesInventors: Lukchiu Li, Edward Anthony Pec, Daniel H. Robinson, Dennis A. Stephens, Kathee Jantzi, Thomas Barton May, John Paul Oberdier
-
Publication number: 20020025296Abstract: A method and use of a labelled compound for monitoring the transfer of a foreign gene including selecting the foreign gene which has been isolated from a cell or virus and transferred into a cell population and selecting the labelled compound which will interact selectively with a protein expressed by the foreign gene to produce a labelled product. The labelled compound has a rate of expulsion from the cells which is greater than that of the labelled product. Further, the use and method include administering to the cells an effective dose of the labelled compound such that the labelled compound selectively interacts with the protein to produce the labelled product, waiting a period of time such that a substantial amount of the labelled compound has been expelled from the cells and such that a detectable amount of the labelled product remains and determining the extent and location of the protein by detecting the labelled product.Type: ApplicationFiled: May 14, 2001Publication date: February 28, 2002Inventors: Edward E. Knaus, Leonard I. Wiebe, Kevin Morin
-
Patent number: 6329498Abstract: The present invention provides a novel salt compound of a polypeptide represented by formula I and a transition metal which has high antiviral activity against human immunodeficiency virus (HIV).Type: GrantFiled: April 14, 1999Date of Patent: December 11, 2001Assignee: Seikagaku CorporationInventors: Akiyoshi Matsumoto, Michinori Waki